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Lipoprotein markers associated 
with disability from multiple 
sclerosis
A. R. Gafson1, T. Thorne  1, C. I. J. McKechnie2, B. Jimenez3, R. Nicholas  1 & 
P. M. Matthews1,2,4
Altered lipid metabolism is a feature of chronic inflammatory disorders. Increased plasma lipids and 
lipoproteins have been associated with multiple sclerosis (MS) disease activity. Our objective was to 
characterise the specific lipids and associated plasma lipoproteins increased in MS and to test for an 
association with disability. Plasma samples were collected from 27 RRMS patients (median EDSS, 
1.5, range 1–7) and 31 healthy controls. Concentrations of lipids within lipoprotein sub-classes were 
determined from NMR spectra. Plasma cytokines were measured using the MesoScale Discovery 
V-PLEX kit. Associations were tested using multivariate linear regression. Differences between the 
patient and volunteer groups were found for lipids within VLDL and HDL lipoprotein sub-fractions 
(p < 0.05). Multivariate regression demonstrated a high correlation between lipids within VLDL 
sub-classes and the Expanded Disability Status Scale (EDSS) (p < 0.05). An optimal model for EDSS 
included free cholesterol carried by VLDL-2, gender and age (R2 = 0.38, p < 0.05). Free cholesterol 
carried by VLDL-2 was highly correlated with plasma cytokines CCL-17 and IL-7 (R2 = 0.78, p < 0.0001). 
These results highlight relationships between disability, inflammatory responses and systemic lipid 
metabolism in RRMS. Altered lipid metabolism with systemic inflammation may contribute to immune 
activation.
Multiple Sclerosis (MS) is a chronic neuroinflammatory disorder and one of the most common non-traumatic 
causes of acquired disability in young adults1. Monitoring progression currently relies on insensitive clinical 
measures and serial brain imaging, as there are no qualified blood biomarkers of disease progression2. Identifying 
such markers could both enable more accurate patient stratification and monitoring of therapeutic interventions.
The association between inflammation and alterations in lipid metabolism is well characterised. The 
pro-inflammatory state, characterised by an immune-cell mediated release of cytokines, can cause a rise in tri-
glyceride rich serum lipoproteins secondary to increases in production and reduced hepatic clearance3,4. This fur-
thers inflammatory cascades through the production of yet more pro-inflammatory cytokines by macrophages, 
for example5. This pattern, as well as an increase in vascular comorbidity are features of a number of chronic 
systemic autoimmune diseases such as rheumatoid arthritis, systemic lupus erythematosus and psoriasis3,6,7.
Previous studies have suggested an association between dyslipidaemia, dyslipoproteinaemia and greater MS 
disease activity (new MRI lesions8,9 or worsening EDSS8,10,11). Furthermore, large metabolomics studies have 
demonstrated that fatty acids, triglycerides, cholesterols and phospholipids can accurately distinguish MS patients 
from healthy controls as well as those with greater clinical disability or at different stages of disease12–14. Lipid 
dysregulation and dyslipoproteinaemia may occur as a secondary by-product of myelin destruction in the central 
nervous system12. Alternatively, they may play a role in immune dysfunction through regulation of cytokine pro-
duction or increased transportation on lipid rafts15. Recently, indirect evidence consistent with a causal role for 
dyslipidaemia in disease progression was provided by results from MS-STAT, a Phase IIa study showing that high 
dose simvastatin reduced rates of brain atrophy and disability progression in patients with secondary progressive 
MS16. Similar findings were not observed in a trial combining atorvastatin with interferon beta suggesting that 
this interaction may be complex17.
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Lipids and lipoproteins can be measured using a number of techniques including ultracentrifugation, high 
performance liquid chromatography and nuclear magnetic resonance (NMR) spectroscopy18. A novel NMR 
method has recently been developed that can measure lipid concentrations (cholesterol, free cholesterol, tri-
glyceride, phospholipids and apolipoproteins) within plasma lipoprotein sub-fractions (lipoproteins subdivided 
based on density and size). This method has the advantages of being amenable to high throughput use, is highly 
reproducible and can provide simultaneous class-specific information on both lipoproteins and their constituent 
lipids, both of which have been associated with MS disease activity19. It promises increased sensitivity to changes 
in circulating lipids related to systemic inflammatory states. Here we tested for an association between MS and 
lipid concentrations within plasma lipoprotein sub-fractions in relapsing-remitting MS patients (RRMS) relative 
to age- and sex- matched healthy volunteers. We also tested for association between these lipid concentrations 
and plasma cytokines, as markers of both systemic inflammatory responses and disability.
Methods
Our research study was reviewed and approved by the NREC Committee of London Camden and Islington 
(NREC 14/LO/1896). All methods were performed in accordance with the relevant guidelines and regulations. 
All patients provided full, informed written consent to participate in the study.
Study Design. Our cohort included 27 patients with RRMS (RRMS; median EDSS, 1.5, range 1–7) diag-
nosed by McDonald criteria20, who were recruited from the Imperial College Healthcare NHS Trust prior to 
commencing a new disease modifying treatment and who consented for participation in the study (Table 1). 
Patients recruited were aged between 18–65 and treatment-free (disease modifying treatments and steroids) for 
at least 3 months as well as relapse-free for at least a month. Any subjects on statin therapies were excluded from 
the analysis. Three patients experienced regular migraines, 2 had asthma, 2 psoriasis and 2 had autoimmune thy-
roid disorders. 31 age- and gender- matched healthy controls were recruited by local advertising or commercially 
sourced. The Expanded Disability Status Score (EDSS) was used to assess disability in the patients and conducted 
by a single, trained physician (AG).
Sample Collection. Non-fasting venous blood samples were collected at study visits in EDTA tubes and cen-
trifuged at 1400 × g for 10 minutes within 3 hours of sample collection. Plasma then was separated immediately 
into aliquots of 1 ml and stored at −80 °C.
NMR Spectroscopy. Plasma samples were centrifuged for 5 minutes at 4 °C at 13,000 rpm to remove solid 
particles in suspension. Samples were prepared as previously described for NMR analysis21. A Bruker 600 Avance 
III spectrometer was used to acquire a 1D NMR general profile, spin-echo and 2D J-res spectra21. Spectra were 
processed, phased and automatically baseline corrected using TopSpin software (v3.2, Bruker, BioSpin, Germany). 
The signal from the anomeric proton of the glucose at 5.23 ppm was used to calibrate the plasma spectra.
Lipoprotein and cytokine analyses. Plasma lipoprotein quantification was performed with the Bruker 
B.I.-LISA (Bruker IVDr Lipoprotein Subclass Analysis) platform using the –CH3 and CH2 resonances in the 
1H-general profile NMR spectrum, which appear at 0.85 and 1.20 ppm, respectively. These broad resonances were 
bucketed and fitted against a Partial Least Square (PLS2) regression model. The model has been validated against 
direct assays after plasma ultracentrifugation19. For each sample, the method estimates total plasma triglyceride, 
cholesterol, free cholesterol, phospholipid and apolipoprotein A1, A2 and B. It also estimates concentrations of 
these lipids (where calculable) within the main lipoprotein classes (VLDL, IDL, LDL, HDL), subdivided accord-
ing to increasing density and decreasing size (VLDL-1 - VLDL-6, LDL-1 - LDL-6, HDL-1 - HDL-4). 105 lipo-
protein sub-fractions were analysed in each sample using this method and a complete list of these are identified 
in Supplementary Table 1. A test-retest comparison of sub-fractions measured in a single healthy control from 
samples taken on 5 consecutive days showed that mean lipoprotein sub-fraction concentrations varied by <5%.
Plasma cytokine analysis was performed using the Meso Scale Discovery (MSD) V-PLEX kit (measuring con-
centrations of 40 cytokines) run as recommended by the manufacturer (Meso Scale Discovery, Maryland, USA). 
Results were read with a MSD Sector Imager 6000 and cytokine concentrations determined with Softmax Pro 
Version 2.5 software using curve fit models.
MS Patients Controls
Gender Men (n = 12) Women (n = 15) 17 Men 14 Women
Mean Age (years) 41.0 ± 13.4 41.9 ± 12.3 40.3 ± 8.6
Average disease duration from diagnosis (years) 4 ± 4 5 ± 4 N/A
Average disease duration from first symptom (years) 9 ± 7 9 ± 7 N/A
EDSS (median, range) 1.5 (1–7.0) 3.0 (1–6.5) N/A
Treatment Naïve patients 7 7 N/A
Current Smoker 2 1 0
Table 1. Patient and healthy volunteer demographic data. Values quoted as mean ± standard deviation if not 
indicated otherwise.
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Statistical Analyses. Descriptive statistics were used to summarise MS patient and healthy control demo-
graphics. For lipoprotein analyses, contrasts between patients and controls were performed using ANOVA (F 
test). If the ANOVA showed a statistically significant difference (p < 0.05), a post hoc analysis was performed 
using Holm-Bonferroni to correct for multiple comparisons. The desired level of significance was set at p < 0.05 
after correction.
Lipids within Lipoprotein sub-fractions that had different concentrations between patients and controls with 
a fold change >1.30 were taken forward for further analyses. Pearson’s correlation coefficients between each pair 
of VLDL sub-fractions were calculated and used to create the matrix of pairwise correlations (Fig. 1a,b).
Correlations between EDSS and lipids and MS patient characteristics were analysed using multivariate linear 
regression models. Due to the high collinearity between the lipids within lipoprotein sub-fractions, which would 
have led to variance inflation in a model22, each lipid sub-fraction was analysed separately using the regression 
model. We included well recognised risk factors of age, gender, disease duration and body mass index (BMI)1. 
EDSS was defined as the dependent variable, with the patient characteristics and lipid measures as predictive 
variables:
= α + α + α + α + α + α .EDSS Lipid (within lipoprotein) Age Gender Disease Duration BMI1 2 3 4 5 6
where coefficients α1,…,α5 determine the contributions of each of the predictor variables to EDSS and α6 expresses 
the residual error. We used analysis of residuals to check the required assumptions of normally distributed errors 
with constant variance. Regression models were corrected for multiple comparisons using Holm-Bonferroni 
method.
These multivariate regression models then were evaluated from their R2 values, residual standard errors and 
the overall p-values. The level of significance was set at p < 0.05. The relative significance of contributions of 
individual predictive variables was assessed by averaging sequential sums of squares obtained from all possible 
orderings of the predictors using the LMG method23. Statistics were evaluated using ‘relaimpo’ package in R24.
We used the Akaike Information Criterion (AIC) to determine the most parsimonious model with the predic-
tor variables available25. These included age, disease duration, sex, BMI and those lipids that were both raised in 
patients compared to controls and correlated with EDSS in the prior multivariate regression analyses. AIC allows 
us to perform model selection to derive a preferred model based on a trade-off between goodness of fit and model 
complexity. These statistics were analysed using the ‘mass’ package in R26. In order to confirm stability of the 
resulting model was unstable, we performed a leave-one-out cross validation removing one patient in turn and 
recording the p-values for each derived model.
To explore associations between cytokines and lipids, we created regression models using the lipid included in 
the most parsimonious model derived from AIC (free cholesterol carried by VLDL-2) and input this into a gen-
eralised linear model via penalised maximum likelihood. To improve the interpretability and accuracy given the 
large number cytokine variables, we used a lasso regression based cross–validation27. Analyses were performed 
using the glmnet package in R28.
Figure 1. (a,b) Matrices illustrating pairwise correlations between VLDL sub-fraction concentrations for 
healthy volunteers (a) and MS patients (b). Abbreviations: TPTG = total plasma triglycerides, V1TG = VLDL-1; 
triglycerides, V1CH = VLDL-1; cholesterol, V1FC = VLDL-1; free cholesterol, V1PL = VLDL-1; phospholipids, 
V2TG = VLDL-2; triglycerides, V2CH = VLDL-2; cholesterol, V2FC = VLDL-2; free cholesterol, V2PL = VLDL-2; 
phospholipids, V3TG = VLDL-3; triglycerides, V3CH = VLDL-3; cholesterol, V3FC = VLDL-3; free cholesterol, 
V3PL = VLDL-3, phospholipids. Bar represents r-value for pairwise correlation.
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Results
Patient demographics and clinical information are provided in Table 1. 13 patients had been on previous disease 
modifying treatment, 14 patients were treatment-naïve. One patient was excluded from the study due to concur-
rent statin treatment.
Lipids within lipoproteins are increased in MS patients compared to healthy controls. A global 
contrast was performed between measures for the MS patients and healthy volunteer groups. We found 23 lipids 
within VLDL and HDL sub-fractions that were increased in the patient group relative to the healthy volunteers 
(Table 2). 13/23 of these lipid concentrations had changes of >1.30-fold in patients relative to the volunteers 
(range, 1.31–2.00-fold) (Table 2). Concentrations of total plasma cholesterol and total plasma triglycerides are 
defined in Supplementary Table 2.
Lipids within VLDL sub-fractions are correlated with disability in people with MS. We then 
tested whether lipid concentrations within lipoprotein sub-fractions elevated in our cohort were correlated 
with MS disease disability. To do this, we used a multivariate regression approach accounting for variance from 
other potential major determinants (see Methods). We found that concentrations of two of the lipids in VLDL-2 
sub-fractions (cholesterol and free cholesterol) but none of the lipids in any HDL sub-fractions were correlated 
with EDSS (Table 3). Strong pairwise correlations were also observed between the relative concentrations of lipids 
within VLDL lipid sub-fractions in the patient and healthy volunteer groups (r >0.5 for all) (Fig. 1a,b).
We assessed the relative contibution of lipid concentrations in VLDL-2 for explaining EDSS using a residual 
sum of squares approach. Total and free cholesterol concentrations in the VLDL-2 sub-fractions accounted for 
the greatest proportions of variance (0.38 and 0.39, respectively) (Fig. 2a,b).
We selected an optimal model based on Akaike Information Criterion (AIC) after incorporating total cho-
lesterol and free cholesterol within VLDL-2 and clinical characteristics. The best quality model excluded BMI, 
disease duration and cholesterol, leaving free cholesterol in VLDL-2, age and gender as the most informative 
explanatory variables. This multivariate regression model described a moderate correlation for EDSS (R2 = 0.37, 
Lipid Sub-Fraction Concentration (mg/dL)
Relative Change 
(patients/controls)
F Test 
(corrected)
Patient Control
VLDL-2
  Free Cholesterol 1.27 (±1.32) 0.97 (±0.81) 1.31 p = 0.03
  Triglycerides 13.66 (±9.99) 9.72 (±5.96) 1.40 p = 0.03
  Phospholipids 3.21 (±2.46) 2.59 (±1.45) 1.24 p = 0.03
  Cholesterol 3.02 (±2.96) 2.04 (±1.47) 1.48 p = 0.003
VLDL-3
  Free Cholesterol 1.49 (±1.50) 1.26 (±0.90) 1.18 p = 0.03
  Triglycerides 11.40 (±8.78) 9.00 (±5.02) 1.27 p = 0.03
  Phospholipids 3.39 (±2.80) 3.08 (±1.64) 1.10 p = 0.03
  Cholesterol 3.67 (±3.60) 3.08 (±1.86) 1.20 p = 0.007
VLDL- 4
  Free Cholesterol 2.21 (±1.97) 1.98 (±1.13) 1.11 p = 0.03
  Triglycerides 8.04 (±5.23) 7.88 (±3.08) 1.02 p = 0.03
  Cholesterol 4.82 (±4.17) 4.62 (±2.34) 1.04 p = 0.02
HDL- 1
  Apolipoprotein-A1 34.4 (±19.1) 20.1 (±9.3) 1.7 p = 0.002
  Apolipoprotein-A2 3.70 (±1.92) 1.85 (±1.04) 2.00 p = 0.01
  Phospholipids 27.70 (±13.00) 17.00 (±7.11) 1.62 p = 0.02
  Cholesterol 22.66 (±10.44) 14.56 (±5.80) 1.56 p = 0.02
  Free Cholesterol 7.30 (±2.56) 4.18 (±1.55) 1.74 p = 0.03
HDL- 2
  Apolipoprotein-A1 21.40 (±6.81) 15.69 (±3.88) 1.36 p = 0.03
  Apolipoprotein-A2 4.17 (±1.59) 2.69 (±0.91) 1.55 p = 0.03
  Phospholipids 15.93 (±5.67) 10.78 (±3.22) 1.48 p = 0.03
  Cholesterol 10.73 (±3.59) 7.28 (±2.19) 1.47 p = 0.03
  Triglycerides 1.95 (±1.00) 1.83 (±0.62) 1.06 p = 0.04
HDL- 3
  Apolipoprotein-A2 8.09 (±2.44) 5.78 (±1.42) 1.40 p = 0.03
  Triglycerides 2.22 (±1.04) 2.07 (±0.60) 1.07 p = 0.03
Table 2. Lipids within VLDL and HDL lipid sub-fractions that were significantly increased in MS patients 
relative to healthy volunteers. Concentrations are quoted in mg/dL ± standard deviation.
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p = 0.0001). The contribution of free cholesterol in VLDL-2 to this model was independently significant 
(p = 0.003). We tested stability of the model using leave-one-out cross validation (LOOCV). For each run of 
LOOCV, the model remained significant (Supplementary Table 3).
Increased plasma cytokine concentrations are associated with raised free cholesterol concen-
trations in VLDL sub-fractions in MS patients. We then tested whether increased plasma cytokines, as 
measures of systemic inflammatory state, were related to concentrations of free cholesterol within the VLDL-2 
lipoprotein sub-fraction. Free cholesterol concentrations within VLDL-2 were used in a general linear model to 
test for associations with plasma cytokine levels. Strong correlations between cholesterol in VLDL-2 and both 
CCL-17 and IL-7 concentrations were found (R2 = 0.78, p < 0.0001).
Discussion
Dyslipidaemia has previously been associated with MS disease activity. Here we extended these observations by 
characterising associations of specific plasma lipoprotein sub-fractions and the concentration of lipids carried 
within them with disease and disability level in people with RRMS. Using a novel NMR analytical methodology, 
we showed that specific lipid concentrations within VLDL and HDL lipoprotein sub-fractions are increased in 
MS patients relative to healthy subjects. We additionally observed correlations between individual lipids carried 
by the VLDL-2 sub-fraction (cholesterol, free cholesterol and triglycerides) and measures of clinical disability 
Lipid Sub-Fraction Model R2 Model P-value Lipid P - value Residual Error
VLDL-2
  Free Cholesterol 0.40 p = 0.0013 p = 0.026 1.78
  Triglycerides 0.39 p = 0.0026 p = 0.052 1.80
  Cholesterol 0.39 p = 0.0026 p = 0.030 1.79
HDL-1
  Apolipoprotein-A1 0.28 NS NS 2.08
  Apolipoprotein-A2 0.27 NS NS 2.09
  Phospholipids 0.28 NS NS 2.08
  Cholesterol 0.29 NS NS 2.06
  Free Cholesterol 0.29 NS NS 2.06
HDL- 2
  Apolipoprotein-A1 0.27 NS NS 2.10
  Apolipoprotein-A2 0.28 NS NS 2.08
  Phospholipids 0.28 NS NS 2.08
  Cholesterol 0.27 NS NS 2.09
HDL- 3
  Apolipoprotein-A2 0.30 NS NS 2.05
Table 3. Statistical measures of fit for each lipid within VLDL and HDL sub-fractions with corresponding 
corrected p-value, residual standard errors for the regression model and corrected p-value for the lipid predictor 
coefficient. NS = not significant.
Figure 2. (a,b) Relative weighting of variables to multivariate regression models for VLDL-2 (free cholesterol 
and cholesterol). Values expressed as percentage of R2 with 95% confidence intervals. Abbreviations: 
DD = Disease Duration; V2CH = VLDL-2; cholesterol, V2FC = VLDL-2; free cholesterol.
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(EDSS) in the MS patients. Separate analyses based on concentrations of these lipids within VLDL-2 showed 
that total and free cholesterol were the strongest explanatory variables for EDSS. The correlation of free choles-
terol within VLDL-2 and plasma concentrations of the CCL-17 and IL-7 cytokines both highlights that systemic 
inflammation alters lipid metabolism and suggests that altered lipid metabolism may enhance immune responses.
This study took an unbiased approach by initially performing a global lipoprotein analysis using a recently 
developed NMR spectroscopy method that allows the simultaneous quantification of a large number of lipid con-
centrations within lipoprotein sub-fractions19. This method is unique from traditional lipoprotein quantification 
as it takes into account the concentrations of water-insoluble lipids within the supermolecular assemblies. Lipids 
within VLDL and HDL sub-fractions were consistently elevated in the patient cohort compared with healthy 
volunteers. Relative concentrations of a subset of these lipids within VLDL-2 sub-fractions only were correlated 
with disease disability. Whilst age and gender have previously been associated with a poorer prognosis in MS29, 
VLDL-2 (free cholesterol and cholesterol) sub-fractions independently explained as much of the variance in 
disability as age.
The relationship is not new. A number of previous studies have reported that plasma lipids such as cholesterol 
and their carrier lipoproteins are raised in MS and that increases are correlated with disease disability9,10,30,31. A 
recent paper corroborates our findings of both raised triglyceride-rich VLDL and HDL in RRMS patients com-
pared to controls32. The protective association of HDL with MS severity is consistent with our finding that lipids 
within HDL specifically were not associated with worsening MS disability.
In this study, we identified novel associations between specific lipids within VLDL sub-fractions and MS dis-
ability. Increases in VLDL levels33 also have been reported during other inflammatory disorders such as rheuma-
toid arthritis and systemic lupus erythematosus but have not been identified in MS3. The mechanisms responsible 
for the VLDL increases in MS reported here were not investigated directly. However, cytokines increase produc-
tion and reduce clearance of serum triglycerides and VLDL4. Triglyceride-rich VLDL (as well as VLDL remnants 
resulting from lipolysis)34,35 is taken up by monocytes, where it can stimulate pro-inflammatory cytokine produc-
tion via activation of the MAPK pathway, for example5,36. A possible relationship with disability may arise from 
consequently greater numbers of activated monocytes recruited to acute plaques and greater demyelination37, as 
well as exacerbation of blood-brain barrier disruption38.
Here we observed a strong correlation between free cholesterol within VLDL-2 and both CCL-17 and IL-7 
highlighting a potential interaction between inflammation and dyslipidaemia. CCL-17 has been shown to play a 
role in T cell maturation. A common polymorphism in the IL-7 receptor gene is a known genetic risk factor for 
MS39. Statins are reported to lower both VLDL40,41 and various cytokines including IL-742.
The main limitations of this pilot study were methodological. Our samples were taken non-fasting and our 
healthy control population was not matched for diet with our MS population. However, this would have altered 
a urine metabolomic profile more than a plasma metabolomic profile and we included BMI as a potential con-
founder in the regression model. The cross-sectional nature of the study, the small sample size and the lack of a 
validation cohort were further limitations however the use of leave-one out cross validation removed the potential 
effect of an outlier. While commonly used in the general population, only one patient in our study group was on 
lipid-lowering medication, and this patient was eliminated from the analyses.
In conclusion, we have provided evidence that specific lipid concentrations within VLDL sub-fractions are 
correlated both with disability in RRMS patients and with pro-inflammatory plasma cytokine levels. These find-
ings highlight relationships between systemic metabolism (particularly involving the liver where VLDLs are syn-
thesised), inflammation and MS43. They suggest that clinical benefits of lipid lowering drugs with inflammatory 
diseases may be realised by decreasing plasma lipid concentrations and, through this, by reducing associated 
monocyte activation. Prospective studies exploring how concentrations of lipids within VLDL sub-classes evolve 
through the disease course will help to determine the prognostic value of these measures in predicting disability 
progression.
Data Availability Statement
The datasets generated during and/or analysed during the current study are available from the corresponding 
author on reasonable request.
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